



Third Meeting (MOP 3, 13-17 March 2006, Curitiba, Brazil)

- ☐ Additional guidance may be required on specific aspects of RARM
 - •on particular types of LMOs,
 - •particular intended uses of LMOs,
 - •particular types of risks,
 - •particular receiving environments,
 - •long-term monitoring of LMOs released into the environment,
- ☐ Consider at its fourth meeting the appropriate modalities for development of any such guidance.





Open-ended Online Expert Forum on RARM

8 ad hoc online discussion groups on specific topics of RARM (Nov – Dec, 2008)


- ≻Fish
- > trees,
- > microorganisms and viruses,
- >pharmaplants,
- >stacked genes or traits,
- ➤ Post-release monitoring and long-term effects of LMOs released into the environment,
- > RARM of specific receiving environments and
- ➤ Roadmap for RA
- 4 Regional (Europe, Africa, Asia and Latin America) Real-Time Online Conferences (Jan –Feb 2009)



First Meeting of the AHTEG (20 -24 April 2009, Montreal)

Members of the AHTEG

- **I. Eighteen participants** from **seventeen Parties** (Austria, Belize, Brazil, China, Croatia, Cuba, Egypt, Germany, Japan, Malaysia, Mexico, Netherlands, Niger, Nigeria, Norway, Republic of Moldova and Slovenia),
- **II. Eight observers** from three **non-Parties** (Australia, Canada, United States of America) and **Five organizations** (Bayer CropScience, Federation of German Scientists, Monsanto Company, PRRI and University of Canterbury)





Activities Prior to the Second AHTEG Meeting

- ❖Online discussions within the AHTEG Sub-working Groups for further drafting of the guidance documents (May- June 2009, August − October 2009)
- ❖ Face to Face Meeting of the AHTEG Sub-working Group on the Roadmap and AHTEG Bureau (12 − 14 October 2009, The Hague, Netherlands)
- Online discussions within the AHTEG Sub-working Groups for further drafting of the guidance documents and testing of the Roadmap (November 2009- March 2010)



Second AHTEG Meeting (20-23 April 2010, Ljubljana, Slovenia)

- ☐ Revised and finalised the "Roadmap" for the effective use of guidance documents on RA;
- ☐Made recommendations on how to integrate the "Roadmap" and tools for retrieval of guidance materials available in the BIRC of the BCH relevant at the different stages of RA;
- □Guidance on Risk Assessment of Living Modified Organisms" divided into two main sections entitled "Part I: Roadmap for RA of LMOs" and "Part II: Specific Types of LMOs and Traits".

Several recommendations were made to COP-MOP 5

- Publish and distribute in all UN languages
- Further testing
- ❖Should be revisited within 2 years
- ❖ Develop additional guidance documents



Fifth Meeting (MOP 5, 11-15 October, Nagoya, Japan)

Decided to extend the current open-ended online forum and the AHTEG on RARM

- ☐ Revise and test the first version of the Guidance;
- ☐ Assess the overall applicability and utility of the Guidance;

To have the following outcomes:

- A revised version of the "Guidance on Risk Assessment of Living Modified Organisms";
- A mechanism, including criteria, for future updates of the lists of background materials;
- Further guidance on new specific topics of RA,



Activities Prior to the Third AHTEG

- Scientific review between 4 February and 15 March 2011(18 Parties, two other Governments and 12 organizations)
- Online discussion groups under the Open-ended Online Forum (28 March -18 April 2011)
- Chair prepared a draft revised text based on comments resulting from on-line discussions and the scientific reviews



Third AHTEG Meeting (Mexico City ,30 May - 3 June 2011)

- √ Revised Draft -basis for further work through the Open-ended Online Forum
- √Two additional guidance documents to be developed:
 - •Post-Release Monitoring and Long-Term Effects of LMOs released into the environment; and
 - •Risk assessment of Living Modified Trees

Fourth AHTEG to be held before COP-MOP 6



PART I Roadmap For RISK ASSESSMENT of Living Modified Organisms

Background , Introduction , Overarching Issues in the Risk Assessment Process, Planning Phase of the Risk Assessment; and

Conducting the Risk Assessment

- Step 1 An identification of any novel characteristics that may have adverse effects
- •Step 2 An evaluation of the likelihood of adverse effects being realized, taking into account the level and kind of exposure of the likely potential receiving environment to the LMO
- •Step3 An evaluation of the consequences should these adverse effects be realized
- \bullet Step 4 An estimation of the overall risk posed by the LMO based on the evaluation of the likelihood and consequences of the identified adverse effects being realized
- •Step 5 A recommendation as to whether or not the risks are acceptable or manageable, including, where necessary, identification of strategies to manage these risks



ACTIVITIES TO LOOK OUT FOR:

- □23 January 3 February 2012: Online discussion of Guidance documents after consolidation of comments and scientific editing
- □27 February 30 March 2012: Real-time online regional conferences
- ☐ 7-11 May : 4th Meeting of AHTEG
- ☐ 1-5 October: Sixth meeting of the Conference of the Parties serving as the Meeting of the Parties to the Cartagena Protocol on Biosafety (MOP 6)- Hydrebad, India.



12 Sept- 15 Dec 2011 – Testing of the Draft Revised Guidance on RA of LMO

CBD Workshops On Risk Assessment of LMOs

- >12 16 July 2010, Siem Reap, Cambodia
- ≥26 30 September 2011, Belize City, Belize
- >7 11 November 2011, Havana, Cuba
- > 12-16 December 2011, Accra,



Guidance On Risk Assessment Of Living Modified Organisms

- •"RA should be carried out in a scientifically sound and transparent manner, take into account expert advice of & guidelines developed by relevant Int. Orgs"
- •RA should be carried out on a case-by-case basis.
- ullet The required information may vary in nature and level of detail depending on the LMO

IT IS INTENDED TO BE A "LIVING DOCUMENT" THAT WILL BE AND MUST BE MODIFIED AND IMPROVED AS AND WHEN MANDATED BY THE PARTIES TO THE CPB. PARTIES SHOULD ENSURE THAT THESE DOCUMENTS ARE "USER-FRIENDLY" AND GUIDANCE SHOULD BE RELEVANT TO THE SAFETY ASSESSMENT OF THE PARTICULAR LMO.

